 Matthew Malone
Concepts (192)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Foot | 22 | 2024 | 76 | 7.410 |
Why?
| | Diabetes Mellitus | 14 | 2024 | 315 | 3.350 |
Why?
| | Wound Healing | 16 | 2025 | 219 | 2.630 |
Why?
| | Soft Tissue Infections | 9 | 2024 | 18 | 2.290 |
Why?
| | Osteomyelitis | 7 | 2024 | 125 | 2.160 |
Why?
| | Extracorporeal Membrane Oxygenation | 4 | 2025 | 293 | 1.580 |
Why?
| | Bacteria | 4 | 2021 | 220 | 1.500 |
Why?
| | Bandages | 3 | 2025 | 28 | 1.350 |
Why?
| | Metagenomics | 2 | 2021 | 40 | 1.330 |
Why?
| | Bone and Bones | 2 | 2023 | 494 | 1.110 |
Why?
| | Biofilms | 5 | 2021 | 190 | 1.000 |
Why?
| | Anti-Infective Agents | 4 | 2020 | 106 | 0.930 |
Why?
| | Anti-Bacterial Agents | 4 | 2024 | 801 | 0.820 |
Why?
| | Gene Expression Profiling | 4 | 2023 | 1110 | 0.800 |
Why?
| | Varicose Ulcer | 2 | 2024 | 7 | 0.770 |
Why?
| | Databases, Factual | 2 | 2025 | 706 | 0.760 |
Why?
| | Legionnaires' Disease | 1 | 2021 | 3 | 0.740 |
Why?
| | Respiratory Insufficiency | 2 | 2024 | 114 | 0.740 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 12 | 0.730 |
Why?
| | Humans | 50 | 2025 | 52336 | 0.720 |
Why?
| | Coinfection | 1 | 2021 | 44 | 0.690 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 91 | 0.680 |
Why?
| | Wound Infection | 5 | 2024 | 32 | 0.680 |
Why?
| | Virulence Factors | 1 | 2021 | 80 | 0.670 |
Why?
| | Histocytochemistry | 1 | 2019 | 45 | 0.640 |
Why?
| | Bacteriological Techniques | 1 | 2019 | 41 | 0.640 |
Why?
| | Catheters, Indwelling | 1 | 2019 | 57 | 0.620 |
Why?
| | Infusions, Intravenous | 1 | 2019 | 220 | 0.610 |
Why?
| | Catheterization, Central Venous | 1 | 2019 | 82 | 0.590 |
Why?
| | Hospitals | 1 | 2019 | 181 | 0.570 |
Why?
| | Wounds and Injuries | 4 | 2025 | 305 | 0.550 |
Why?
| | Retrospective Studies | 16 | 2025 | 6578 | 0.530 |
Why?
| | Communicable Disease Control | 1 | 2016 | 38 | 0.520 |
Why?
| | Communicable Diseases | 1 | 2016 | 55 | 0.500 |
Why?
| | Intensive Care Units, Pediatric | 3 | 2025 | 146 | 0.490 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2020 | 220 | 0.410 |
Why?
| | Treatment Outcome | 7 | 2025 | 5407 | 0.400 |
Why?
| | Staphylococcal Infections | 2 | 2024 | 280 | 0.340 |
Why?
| | Male | 15 | 2025 | 26696 | 0.330 |
Why?
| | Middle Aged | 10 | 2024 | 13014 | 0.330 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2020 | 561 | 0.320 |
Why?
| | Prospective Studies | 4 | 2024 | 2428 | 0.310 |
Why?
| | Female | 14 | 2025 | 28105 | 0.310 |
Why?
| | Child | 8 | 2025 | 7157 | 0.290 |
Why?
| | Aged | 8 | 2024 | 10109 | 0.290 |
Why?
| | Intubation, Intratracheal | 2 | 2025 | 118 | 0.260 |
Why?
| | Medical Staff, Hospital | 1 | 2025 | 16 | 0.230 |
Why?
| | Patient Handoff | 1 | 2025 | 15 | 0.230 |
Why?
| | Carboxymethylcellulose Sodium | 1 | 2024 | 2 | 0.230 |
Why?
| | Limb Salvage | 1 | 2024 | 40 | 0.230 |
Why?
| | Patient Admission | 1 | 2025 | 78 | 0.230 |
Why?
| | Venous Insufficiency | 1 | 2024 | 6 | 0.220 |
Why?
| | Foot Ulcer | 1 | 2023 | 3 | 0.220 |
Why?
| | Shock, Septic | 1 | 2025 | 70 | 0.220 |
Why?
| | Patient Transfer | 1 | 2025 | 99 | 0.220 |
Why?
| | Monckeberg Medial Calcific Sclerosis | 1 | 2023 | 1 | 0.210 |
Why?
| | Fellowships and Scholarships | 1 | 2025 | 127 | 0.210 |
Why?
| | Tetanus | 1 | 2023 | 3 | 0.200 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 80 | 0.200 |
Why?
| | Skin Diseases, Bacterial | 1 | 2022 | 14 | 0.200 |
Why?
| | Insulins | 1 | 2022 | 1 | 0.200 |
Why?
| | Disease | 1 | 2022 | 25 | 0.200 |
Why?
| | Transcriptome | 2 | 2023 | 367 | 0.200 |
Why?
| | Peripheral Arterial Disease | 1 | 2024 | 75 | 0.200 |
Why?
| | Arthropathy, Neurogenic | 1 | 2022 | 7 | 0.200 |
Why?
| | Biopsy, Fine-Needle | 1 | 2023 | 107 | 0.200 |
Why?
| | Referral and Consultation | 1 | 2025 | 292 | 0.200 |
Why?
| | Skin | 2 | 2024 | 418 | 0.200 |
Why?
| | Aged, 80 and over | 3 | 2024 | 3391 | 0.200 |
Why?
| | DNA Transposable Elements | 1 | 2023 | 107 | 0.200 |
Why?
| | Pilot Projects | 2 | 2024 | 719 | 0.200 |
Why?
| | Microscopy, Electron, Scanning | 2 | 2019 | 45 | 0.200 |
Why?
| | Australia | 2 | 2019 | 90 | 0.190 |
Why?
| | Periodicals as Topic | 1 | 2022 | 61 | 0.190 |
Why?
| | Sepsis | 1 | 2025 | 229 | 0.190 |
Why?
| | Urinary Incontinence | 1 | 2022 | 40 | 0.190 |
Why?
| | Carotid Arteries | 1 | 2022 | 76 | 0.190 |
Why?
| | Adult | 5 | 2024 | 14139 | 0.190 |
Why?
| | Clinical Competence | 1 | 2025 | 404 | 0.190 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2021 | 8 | 0.190 |
Why?
| | Severity of Illness Index | 2 | 2024 | 1021 | 0.180 |
Why?
| | Brugada Syndrome | 1 | 2021 | 4 | 0.180 |
Why?
| | Catheterization | 1 | 2022 | 95 | 0.180 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2019 | 263 | 0.180 |
Why?
| | Bacterial Infections | 1 | 2022 | 98 | 0.180 |
Why?
| | Proteomics | 1 | 2024 | 326 | 0.180 |
Why?
| | Iodophors | 1 | 2021 | 1 | 0.180 |
Why?
| | Streptococcus | 1 | 2021 | 16 | 0.180 |
Why?
| | Staphylococcus aureus | 2 | 2022 | 331 | 0.180 |
Why?
| | Virulence | 1 | 2021 | 167 | 0.180 |
Why?
| | Muscle Development | 1 | 2021 | 24 | 0.180 |
Why?
| | Critical Illness | 1 | 2023 | 292 | 0.180 |
Why?
| | Surface-Active Agents | 1 | 2021 | 10 | 0.180 |
Why?
| | Adolescent | 5 | 2025 | 6692 | 0.180 |
Why?
| | Tachycardia, Ventricular | 1 | 2021 | 46 | 0.180 |
Why?
| | Length of Stay | 1 | 2024 | 659 | 0.170 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 99 | 0.170 |
Why?
| | Defibrillators, Implantable | 1 | 2021 | 68 | 0.170 |
Why?
| | Phylogeny | 1 | 2021 | 234 | 0.170 |
Why?
| | Host-Pathogen Interactions | 1 | 2021 | 144 | 0.160 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2022 | 187 | 0.160 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 187 | 0.160 |
Why?
| | Pseudomonas aeruginosa | 1 | 2019 | 77 | 0.160 |
Why?
| | Blood Sedimentation | 3 | 2024 | 16 | 0.160 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2024 | 606 | 0.150 |
Why?
| | Catheterization, Peripheral | 1 | 2019 | 49 | 0.150 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 315 | 0.150 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 230 | 0.150 |
Why?
| | Drug Resistance, Bacterial | 1 | 2018 | 81 | 0.150 |
Why?
| | Prostatic Neoplasms | 1 | 2022 | 400 | 0.150 |
Why?
| | C-Reactive Protein | 3 | 2024 | 155 | 0.150 |
Why?
| | Shoes | 1 | 2018 | 14 | 0.140 |
Why?
| | Chronic Disease | 2 | 2017 | 583 | 0.140 |
Why?
| | Anti-Infective Agents, Local | 1 | 2017 | 30 | 0.140 |
Why?
| | Emergency Medicine | 1 | 2017 | 51 | 0.140 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 487 | 0.130 |
Why?
| | Sensitivity and Specificity | 3 | 2024 | 879 | 0.130 |
Why?
| | Consensus | 1 | 2017 | 180 | 0.130 |
Why?
| | Faculty, Medical | 1 | 2017 | 91 | 0.130 |
Why?
| | Lemur | 1 | 2016 | 1 | 0.130 |
Why?
| | Infant | 4 | 2025 | 3684 | 0.120 |
Why?
| | Child, Preschool | 4 | 2025 | 4030 | 0.120 |
Why?
| | Telemedicine | 1 | 2022 | 493 | 0.120 |
Why?
| | Incidence | 3 | 2024 | 1059 | 0.120 |
Why?
| | Ecosystem | 1 | 2016 | 96 | 0.120 |
Why?
| | Patient Education as Topic | 1 | 2018 | 321 | 0.110 |
Why?
| | Neoplasms | 1 | 2024 | 1305 | 0.110 |
Why?
| | Models, Biological | 1 | 2016 | 743 | 0.110 |
Why?
| | Biomedical Research | 1 | 2016 | 256 | 0.100 |
Why?
| | Risk Factors | 4 | 2024 | 3872 | 0.100 |
Why?
| | Time Factors | 1 | 2019 | 2957 | 0.100 |
Why?
| | Punctures | 2 | 2023 | 52 | 0.100 |
Why?
| | Lower Extremity | 2 | 2024 | 99 | 0.100 |
Why?
| | Registries | 2 | 2025 | 580 | 0.090 |
Why?
| | United States | 3 | 2025 | 5182 | 0.080 |
Why?
| | Administration, Topical | 2 | 2020 | 60 | 0.080 |
Why?
| | Infant, Newborn | 2 | 2025 | 2826 | 0.070 |
Why?
| | Israel | 1 | 2024 | 10 | 0.060 |
Why?
| | Pressure Ulcer | 1 | 2024 | 16 | 0.060 |
Why?
| | Exudates and Transudates | 1 | 2024 | 4 | 0.060 |
Why?
| | Debridement | 1 | 2024 | 48 | 0.050 |
Why?
| | Thinness | 1 | 2023 | 44 | 0.050 |
Why?
| | Veins | 1 | 2024 | 74 | 0.050 |
Why?
| | Physical Examination | 1 | 2024 | 99 | 0.050 |
Why?
| | Tetanus Toxoid | 1 | 2023 | 5 | 0.050 |
Why?
| | Surgical Wound Infection | 1 | 2024 | 117 | 0.050 |
Why?
| | Communication | 1 | 2025 | 257 | 0.050 |
Why?
| | Recurrence | 1 | 2024 | 672 | 0.050 |
Why?
| | Fracture Fixation, Internal | 1 | 2022 | 42 | 0.050 |
Why?
| | RNA, Bacterial | 1 | 2022 | 55 | 0.050 |
Why?
| | Ulcer | 1 | 2022 | 25 | 0.050 |
Why?
| | Logistic Models | 1 | 2025 | 920 | 0.050 |
Why?
| | Patient Readmission | 1 | 2024 | 243 | 0.050 |
Why?
| | Prostatectomy | 1 | 2022 | 84 | 0.050 |
Why?
| | Pelvic Floor | 1 | 2022 | 52 | 0.050 |
Why?
| | Overweight | 1 | 2023 | 224 | 0.050 |
Why?
| | Exercise Therapy | 1 | 2022 | 100 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 270 | 0.040 |
Why?
| | Death, Sudden, Cardiac | 1 | 2021 | 59 | 0.040 |
Why?
| | Bacterial Load | 1 | 2020 | 12 | 0.040 |
Why?
| | Amnion | 1 | 2020 | 13 | 0.040 |
Why?
| | Perfusion | 1 | 2020 | 48 | 0.040 |
Why?
| | Cryopreservation | 1 | 2020 | 41 | 0.040 |
Why?
| | Environmental Microbiology | 1 | 2019 | 7 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2023 | 1214 | 0.040 |
Why?
| | Pseudomonas Infections | 1 | 2019 | 54 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 1676 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2019 | 115 | 0.040 |
Why?
| | Electrocardiography | 1 | 2021 | 267 | 0.040 |
Why?
| | Environment | 1 | 2019 | 88 | 0.040 |
Why?
| | Seizures | 1 | 2021 | 208 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 261 | 0.040 |
Why?
| | Animals | 3 | 2019 | 13523 | 0.040 |
Why?
| | Disease Management | 1 | 2020 | 188 | 0.040 |
Why?
| | Heart Failure | 1 | 2024 | 571 | 0.040 |
Why?
| | Foot Orthoses | 1 | 2018 | 7 | 0.040 |
Why?
| | Thinking | 1 | 2017 | 19 | 0.040 |
Why?
| | Oxygen | 1 | 2020 | 336 | 0.040 |
Why?
| | Education | 1 | 2017 | 40 | 0.030 |
Why?
| | Peptide Nucleic Acids | 1 | 2017 | 18 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2018 | 70 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 468 | 0.030 |
Why?
| | Cytokines | 1 | 2020 | 625 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2017 | 68 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 84 | 0.030 |
Why?
| | Tooth Wear | 1 | 2016 | 1 | 0.030 |
Why?
| | Madagascar | 1 | 2016 | 3 | 0.030 |
Why?
| | Quality of Life | 1 | 2022 | 868 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 73 | 0.030 |
Why?
| | Qualitative Research | 1 | 2017 | 362 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 360 | 0.030 |
Why?
| | Risk Assessment | 1 | 2018 | 1323 | 0.030 |
Why?
|
|
Malone's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|